Participant flow

Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E) · Source last updated 2026-09-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Patients receive larotrectinib (LOXO-101) 100 mg PO BID on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT or MRI during screening and on study, as well as during follow-up as clinically necessary. Patients also undergo biopsies and blood sample collection on study.

   id

   FG000

   title

   Treatment (Larotrectinib [LOXO-101])

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Ineligible

   2. reasons

      1. group Id

         FG000

         num Subjects

         3

      type

      Mutation Status Not Confirmed

   3. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Adverse Event

   4. reasons

      1. group Id

         FG000

         num Subjects

         8

      type

      Disease Progression

   5. reasons

      1. group Id

         FG000

         num Subjects

         3

      type

      Still on Therapy

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         16

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         16

      type

      Started Protocol Therapy

   3. achievements

      1. group Id

         FG000

         num Subjects

         15

      type

      Eligible

   4. achievements

      1. group Id

         FG000

         num Subjects

         12

      comment

      Primary efficacy analysis set

      type

      Eligible, Treated and Mutation Status Confirmed

   5. achievements

      1. group Id

         FG000

         num Subjects

         0

      type

      COMPLETED

   6. achievements

      1. group Id

         FG000

         num Subjects

         16

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

Patients were assigned to subprotocol Z1E if an NTRK fusion-positive tumor was identified. The mutation status was determined by an NCI-MATCH approved laboratory for all 16 patients in this arm. These cases had to be confirmed to be used in primary analysis.

recruitment Details

Subprotocol Z1E was activated on March 13, 2017. Between August 21, 2017, and July 8, 2021, 16 patients were enrolled in subprotocol Z1E. All were enrolled on the basis of the outside assay results.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Independent clinical review pending · Not medical advice